Hypertension to heart failure: A pathophysiological spectrum relating blood pressure, drug treatments and stroke

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 6, 2009, Pages 703-713

  Subramaniam, Veeran ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Cerebrovascular disease; Heart failure; Hypertension; Hypertension treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; LOSARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DISEASE COURSE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTOLIC HEART FAILURE; THROMBOSIS; ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; STROKE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; RISK FACTORS; STROKE;

EID: 68849094997     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.43     Document Type: Review

References (121)

1. World Health Organization. Risks to health. In: The World Health Report 2002. World Health Organization, Geneva, Switzerland (2002).
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective studies collaboration: age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1912 (2002).
3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 275, 1557-1562 (1996).
4. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham Study. N. Engl. J. Med. 287, 781-787 (1972).
5. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch. Intern. Med. 156, 1789-1796 (1996).
6. Lloyd-Jones DM, Larson MG, Leip EP et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106, 3068-3072 (2002).
7. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. Am. J. Coll. Cardiol. 32(Suppl. A), A6-A13 (1993).
8. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N. Engl. J. Med. 285, 1441-1446 (1971).
9. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281-1285 (1991).
10. Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 278, 212-216 (1997).
11. O'Malley K, McCormack P, O'Brien ET. Isolated systolic hypertension: data from the European Working party on High Blood Pressure in the Elderly. J. Hypertens. 6, S105-S108 (1988).
12. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293, 1145-1151 (1986).
13. Cleland JGF, Daubert JC, Erdmann E et al. Cardiac Resynchronization-Heart Failure (CARE-HF) study investitagtors. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539-1549 (2005).
14. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 22, 312-318 (1991).
15. Seshadri S, Beiser A, Kelly-Hayes M et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 37, 345-350 (2006).
16. Stergiopulos N, Westerhof N. Determinants of pulse pressure. Hypertension 32, 256-559 (1998).
17. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 56, 56-64 (1975).
18. Hood WP, Rackley CE, Rolett EL. Wall stress in the normal and hypertrophied human left ventricle. Am. J. Cardiol. 22, 550-558 (1968).
19. Koren MJ. Devereux RB, Casale PN. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114, 345-352 (1991).
20. Meerson FZ. On the mechanism of compensatory hyperfunction and insufficiency of the heart. Cor. Vasa. 3, 161-177 (1961).
21. Esposito G, Rapacciuolo A, Naga Prasad SV et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85-92 (2002).
22. Perrino C, Naga Prasad SV, Mao L et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547-1560 (2006).
23. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart; a new therapeutic target? Circulation 109, 1580-1589 (2004).
24. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol. Dial. Transplant. 21, 20-23 (2006).
25. Diez J, Querejeta R, Lopez B, Arantxa G, Mariano L, Ubago M. Losartan dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105, 2512-2517 (2002).
26. Scheuer J, Buttrick P. The cardiac hypertrophy responses to pathological and physiological loads. Circulation 75, 63-68 (1987).
27. Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR, Lerman A. Attenuated coronary flow reserve in patients with hypertension and left ventricular hypertrophy. J. Am. Coll. Cardiol. 35, 1645-1660 (2000).
28. Scheuer J, Malhotta A, Hirsch C, Capasso J, Schaible TF. Physiological cardiac hypertrophy corrects protein abnormalities associated with pathological hypertrophy in rats. J. Clin. Invest. 70, 1300-1305 (1982).
29. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and non-failing human heart. Circ. Res. 86, 386-390 (2000).
30. Calderone A, Takashashi N, Izzo NJ Jr, Thaik CM, Colucci WS. Pressure and volume induced left ventricular hypertrophies are associated with distinct myocytes phenotypes and differential induction of peptide growth factor mRNAs. Circulation 92, 2385-2390 (1995).
31. Hill JA, Olson EN. Cardiac plasticity. N. Engl. J. Med. 358, 1370-1380 (2008).
32. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a "set up" for vascular disease. Circulation 103, 139 (2003).
33. Clement DL, De Buyzere ML, De Bacquer DA et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N. Engl. J. Med. 348, 2407-2415 (2003).
34. Cuspidi C, Meani S, Salerno M. Cardiovascular target organ damage in essential hypertension with or without reproducible nocturnal fall in blood pressure. J. Hypertens. 22, 273-280 (2004).
35. Goyal D, MacFadyen RJ, Watson RD, Lip GY. Ambulatory blood pressure monitoring in heart failure; a systematic review. Eur. J. Heart Fail. 7, 149-156 (2005).
36. Lee KW, Blann AD, Lip GY. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am. J. Hypertens. 18, 104-115 (2005).
37. Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension 46, 185-193 (2005).
38. Sugden PH. Mechanotransduction in cardiomyocytes hypertrophy. Circulation 103, 1375-1377 (2001).
39. Baines CP, Molkentin JD. Stress signalling pathways that modulate cardiac myocytes apoptosis. J. Mol. Cell Cardiol. 38, 47-62 (2005).
40. Banfi C, Cavalca V, Veglia F et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur. Heart J. 26, 481-488 (2005).
41. Yang DK, Choi BY, Lee YH et al. Gene profiling during regression of pressure overload-induced cardiac hypertrophy. Pbysiol. Genom. 30, 1-7 (2007).
42. Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am. J. Physiol Heart Circ. Physiol. 294, H645-H650 (2008).
43. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardisation and comparison to other methods. Hypertenison 9, 119-126 (1987).
44. Opie LH, Commerford PJ, Gersh B, Pfeffer MA. Controversies in ventricular remodeling. Lancet 367, 356-367 (2006).
45. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol. 19, 1550-1558 (1992).
46. Segers P, Stergiopulos N, Westerhof N. Quantification of the contribution of cardiac and arterial remodeling to hypertension. Hypertension 36, 760-765 (2000).
47. Gerdts E. Left ventricular structure in different types of chronic pressure overload. Eur. Heart J. 10, E23-E30 (2008).
48. Grosse P, Jullien V, Jarnier P, Lemetayer P, Clementy J. Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of text ventricular mass? J. Hum. Hypertens. 13, 505-509 (1999).
49. Huber D, Grimm J, Koch R, Krayenbuehl HP. Determinants of ejection performance in aortic stenosis. Circulation 64, 126-134 (1981).
50. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27, 92-98 (2002).
51. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J. Am. Coll. Cardiol. 48, 89-96 (2006).
52. Kim S, Ohta K, Hamaguchi A et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J. Pharmacol. Exp. Ther. 273, 509-515 (1995).
53. Devereux RB, Roman MJ, Paranicas M et al. A population based assessment of left ventricular systolic dysfunction in middle aged and older adults: the Strong Heart Study. Am. Heart J. 141, 436-446 (2001).
54. Devereux RB, Bella JN, Palmieri V et al. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: the Hypertension Genetic Epidemiology Network (HyperGEN) study. Hypertension 38, 417-423 (2001).
55. Wachtell K, Rokkedal J, Bella JN et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE Study). Am. J. Cardiol. 87, 54-60 (2001).
56. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of risk of coronary heart disease. The Framingham Study. Ann. Intern. Med. 72, 813-822 (1970).
57. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561-1566 (1990).
58. Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 43, 2207-2215 (2004).
59. Tsang TS, Barnes ME, Gersh BJ et al. Prediction of risk for first age related cardiovascular events in an elderly population: the incremental value of echocardiography. J. Am. Coll. Cardiol. 42, 1199-1205 (2003).
60. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic value of left ventricular mass and geometry in systemic hypertension n with left ventricular hypertrophy. Am. J. Cardiol. 78, 197-202 (1996).
61. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292, 2350-2556 (2004).
62. Palmieri V, Dahlof B, DeQuattro V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J. Am. Coll. Cardiol. 34, 1625-1632 (1999).
63. Agabiti-Rosei E, Muiesan ML, Salvetti M. New approaches in the assessment of left ventricular hypertrophy. Ther. Adv. Cardiovasc. Dis. 1, 119-128 (2007).
64. Bluemke DA, Kronmal RA, Joao AC et al. The relationship of left ventricular mass and geometry to incident cardiovascular events. The MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 52, 2148-2155 (2008).
65. Cerrato P, Grasso M, Imperiale D. Stroke in young patients: etiopathogenesis and risk factors in different age classes. Cerebrovasc. Dis. 18, 154-159 (2004).
66. Rosenblum WI. Millary aneurisms and "fibrinoid" degeneration of cerebral blood vessels. Hum. Pathol. 8, 133-139 (1997).
67. Miyao S, Takano A, Teramoto J, Takashashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke 23, 1434-1438 (1992).
68. Kuo HK, Lipsitz LA. Cerebral white matter changes and geriatric syndromes: is there a link? J. Gerontol. A Biol. Sci. Med. Sci. 59, 818-826 (2004).
69. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous ihtracerebral haemorrhage. N. Engl. J. Med. 344, 1450-1460 (2001).
70. Welin L, Svardsudd K, Wilhelmesen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N. Engl. J. Med. 317, 521-526 (1987).
71. Bikkina M, Levy D, Evans JC et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA 272, 33-36 (1994).
72. Devereux RB, Pickering TG, Harshfield GA et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 68, 470-476 (1983).
73. Longstreth WT, Manolio TA, Arnold A et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke 27, 2043-2047 (1996).
74. Sierra C, De La Sierra A, Pare JC, Gomez-Angelats E, Coca A. Correlation between silent cerebral white mater lesions and left ventricular mass and geometry in essential hypertension. Am. J. Hypertens. 15, 507-512 (2002).
75. Selvetella G, Notte A, Maffei A et al. Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. Stroke 34, 1766-1770 (2003).
76. Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S. Left ventricular mass and geometry and risk of ischemic stroke. Stroke 34, 2380-2386 (2003).
77. Ganau A, Saba PS, Roman MJ, De Simone G, Realdi G, Devereux RB. Ageing induces left ventricular concentric remodelling in normotensive subjects. J. Hypertens. 13, 1818-1822 (1995).
78. Cuspidi C, Lonati L, Sampieri L et al. Left ventricular concentric remodeling and carotid structural changes in essential hypertension. J. Hypertens. 14, 1441-1446 (1996).
79. Manios E, Tsivgoulis G, Koroboki E et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke 40, 1515-1518 (2009).
80. Drukteinis JS, Romin MJ, Fabsitz RR, Lee ET, Best LG, Russell M. Cardiac and systematic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults - the Strong Hean-Study. Circulation 115, 221-227 (2007).
81. Devereaux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 88, 1444-1455 (1993).
82. Mehta SK, Rame E, Khera A et al. Left ventricular hypertrophy, subclinical atherosclerosis and inflammation. Hypertension 49, 1385-1391 (2007).
83. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am. J. Cardiol. 82, N2-N9 (1998).
84. Tsang TS, Gersh BJ, Appleton CP et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol. 40, 1636-1644 (2002).
85. Hughes M, Lip GY. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation; a systematic review of stroke risk factors, risk stratification scheme and cost effectiveness data. J. Thromb. Haemost. 99, 295-304 (2008).
86. Gladstone DJ, Blakely J, Dorian P et al. EMBRACE pilot study group. Detecting paroxysmal atrial fibrillation after ischemic stroke and transient ischemic attack: if you don't look, you won't find. Stroke 39, E78-E79 (2008).
87. Wachtell K, Devereux RB, Lyle PA, Okin PM, Gerdts E. The left atrium, atrial fibrillation and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Ther. Adv. Cardiovasc. Dis. 2, 507-513 (2008).
88. Lip GYH. Hypertension, platelets and the endothelium; the "Thrombotic Paradox" of hypertension (or Birmingham paradox) revisited. Hypertension 41, 199-200 (2003).
89. Lip GYH. Hypertension and the prothrombotic state. J. Hum. Hypertens. 14, 687-690 (2000).
90. Lip GYH, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 101, 218-220 (2000).
91. Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J. Hum. Hypertens. 8, 693-701 (1994).
92. Lip GYH, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am. J. Cardiol. 80, 1566-1570 (1997).
93. Blann AD. Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul. Fibrinolysis 9, 297-306 (1998).
94. Blann AD, Waite MA. Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Cor. Art. Dis. 7, 143-147 (1996).
95. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin and target organ damage in hypertension: a substudy of the Anglo - Scandinavian Cardiac Outcomes Trials (ASCOT). Hypertension 40, 61-66 (2002).
96. Cuspidi C, Esposito A, Negri F et al. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am. J. Hypertens. 21, 365-366 (2008).
97. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol. 27, 1214-1218 (1996).
98. Okin PM, Devereux RB, Harris KE et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann. Intern. Med. 147, 311-319 (2007).
99. Okin PM, Wachtell K, Devereux RB et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new onset atrial fibrillation in patients with hypertension. JAMA 296, 1242-1248 (2006).
100. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am. J. Hypertens. 19, 493-499 (2006).
101. MacMahon SW, Wilcken DEL, McDonald GJ. The effect of weight reduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N. Engl. J. Med. 314, 334-339 (1986).
102. Ferrara LA, DeSimone G, Pasanisi F, Mancini M, Mancini M. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 6, 755-759 (1984).
103. Rodriguez CJ, Sacco RL, Sciacca RR, Boden-Albala B, Homma S, Di Tullio MR. Physical activity attenuates the effect of increased left ventricular mass on the risk of ischemic stroke: the Northern Manhattan Stroke Study. J. Am. Coll. Cardiol. 39, 1482-1488 (2002).
104. Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 270, 713-724 (1993).
105. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach focus on treatment by antihypertensive agents. Am. J. Hypertens. 11, 1394-1404 (1998).
106. Moser M, Herbert PR. Prevention of disease progression. LVH and CHF in hypertension treatment trials. J. Am. Coll. Cardiol. 27, 1214-1218 (1996).
107. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16, 895-899 (2003).
108. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens. 18, 1465-1475 (2000).
109. Dahlöf B, Gosse P, Guéret P et al. The PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens. 23(11), 2063-2070 (2005).
110. Dahlof B, Bevereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995-1003 (2002)
111. Wachtell K, Palmieri V, Olsen MH et al. Change in systolic left ventricular performance after 3 year of antihypertensive treatment; The Losartan Intervention for Endpoint (LIFE) study. Circulation 106, 227-232 (2002).
112. Verdecchia P, Reboldi G, Angeli F et al. Angiotension-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46, 386-392 (2005).
113. Turnbull F; Blood pressure lowering treatment trialist's collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 362, 1527-1523 (2003).
114. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N. Engl. J. Med. 358-1041 (2000).
115. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 35, 348-350 (2004).
116. Schrader J, Luders S, Kulschewski A et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: principal results of a prospective randomised controlled study (MOSES). Stroke 36, 1218-1226 (2005).
117. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet 358, 1033-1041 (2001).
118. Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
119. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J. Hypertens. 26, 1282-1289 (2008).
120. Yusuf S, Diener HC, Sacco RL et al. PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359, 1225-1237 (2008).
121. Madrid AH, Peng J, Zamora J et al. The role of angiotensin receptor blockers and or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in the patients with cardiovascular disease: meta-analysis of randomised controlled clinical trials. Pacing. Clin. Electrophysiol. 27, 1405-1410 (2004).